2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.
Beksaç, Merak et al.
Paper
Details
#CellularImmunotherapy #PlasmaCellDisorders #2025Update

RBM39 promotes the malignant growth of MM by maintaining the splicing pattern that produces full-length MEK5. buff.ly/zSfSWJb #hemesky #plasmacelldisorders

MYLACRE highlights shortcomings in the management of myeloma in Latin America, with differences between public and private health systems. buff.ly/GqRNkOb #hemesky #plasmacelldisorders #clinicaltrialsandobservations #healthservicesandoutcomes

Survival is predicted by a metabolic tumor volume of ≥25 cm3 at baseline and [18F]FDG-PET/CT response (Bologna criteria) on day 100. https://buff.ly/4gz3fc9 #plasmacelldisorders #immunobiologyandimmunotherapy